Clinical Trials · NCT07389941

Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation

Not Yet RecruitingPhase 4Semaglutide (Investigational)
Phase
Phase 4
Recruitment status
Not Yet Recruiting
Sponsor
University of Luebeck
Enrollment
240
Start date
Oct 2026
Locations
See registry
Primary endpoint
Freedom from atrial arrhythmia (AF/atrial flutter/atrial tachycardia >30 sec) at 12 months post-ablation (8-week-blanking period)
View Semaglutide compound reference